RxDoctor Payments Data

Hassan Hamed, MD

Interventional Cardiology · Wilmington, OHNPI 1659334696

Payments from drug & device makers

$1,720in general payments, 2019–2025

Across 54 payments — averaging $31.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$898
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$155
  • Novartis$123
  • Cardiovascular Systems Inc.$81
  • AstraZeneca$52
  • Cvrx, Inc.$48
  • plus $362 from 16 others

What the payments were for

  • Travel & lodging$77145%
  • Food & beverage$95055%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,720 in reported general payments places this provider in the 25th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$93,651
Medicare patients
529
Services billed
1,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$35,768
Metoprolol Succinate143$1,586
Atorvastatin Calcium73$847
Amiodarone Hcl26$581
Isosorbide Mononitrate ErIsosorbide Mononitrate47$376
Nitroglycerin50$234
Amlodipine Besylate33$132
ClopidogrelClopidogrel Bisulfate30$122
Losartan Potassium17$111
Ezetimibe13$106
Metoprolol Tartrate12$93
Rosuvastatin Calcium15$72
Furosemide19$54
Lisinopril15$48
Carvedilol13$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$35,76845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Wilmington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →